Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study

INTRODUCTION: Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)—collectively named inflammatory arthritis (IA). However, the costs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Adv Ther
Hauptverfasser: Dalén, Johan, Luttropp, Karin, Svedbom, Axel, Black, Christopher M., Kachroo, Sumesh
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Healthcare 2020
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444358/
https://ncbi.nlm.nih.gov/pubmed/32647910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01425-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge